




Instance: composition-en-118afad7684b14db488523a58f186d8f
InstanceOf: CompositionUvEpi
Title: "Composition for tesavel Package Leaflet"
Description:  "Composition for tesavel Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfa38344eb5b5d2eb2ddb54f7e79c6b96)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tesavel"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Tesavel is and what it is used for</li>
<li>What you need to know before you take Tesavel</li>
<li>How to take Tesavel</li>
<li>Possible side effects</li>
<li>How to store Tesavel</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tesavel is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tesavel is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tesavel contains the active substance sitagliptin which is a member of a class of medicines called
DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients
with type 2 diabetes mellitus.
This medicine helps to increase the levels of insulin produced after a meal and decreases the amount
of sugar made by the body.
Your doctor has prescribed this medicine to help lower your blood sugar, which is too high because of
your type 2 diabetes. This medicine can be used alone or in combination with certain other medicines
(insulin, metformin, sulphonylureas, or glitazones) that lower blood sugar, which you may already be
taking for your diabetes together with a food and exercise plan.
What is type 2 diabetes?
Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that
your body produces does not work as well as it should. Your body can also make too much sugar.
When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems
like heart disease, kidney disease, blindness, and amputation.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tesavel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tesavel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Tesavel
- if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in
section 6).
Warnings and precautions
Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving Tesavel
(see section 4).
If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid.
Your doctor may ask you to stop Tesavel.
Tell your doctor if you have or have had:</p>
<ul>
<li>a disease of the pancreas (such as pancreatitis)</li>
<li>gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.
These medical conditions can increase your chance of getting pancreatitis (see section 4).</li>
<li>type 1 diabetes</li>
<li>diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss,
nausea or vomiting)</li>
<li>any past or present kidney problems</li>
<li>an allergic reaction to Tesavel (see section 4)
This medicine is unlikely to cause low blood sugar because it does not work when your blood sugar is
low. However, when this medicine is used in combination with a sulphonylurea medicine or with
insulin, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your
sulphonylurea or insulin medicine.
Children and adolescents
Children and adolescents below 18 years should not use this medicine. It is not effective in children
and adolescents between the ages of 10 and 17 years. It is not known if this medicine is safe and
effective when used in children younger than 10 years.
Other medicines and Tesavel
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines. 
In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heartbeat and
other heart problems). The level of digoxin in your blood may need to be checked if taking with
Tesavel.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine. 
You should not take this medicine during pregnancy.
It is not known if this medicine passes into breast milk. You should not take this medicine if you are
breast-feeding or plan to breast-feed.
Driving and using machines
This medicine has no or negligible influence on the ability to drive and use machines. However,
dizziness and drowsiness have been reported, which may affect your ability to drive or use machines.
Taking this medicine in combination with medicines called sulphonylureas or with insulin can cause
hypoglycaemia, which may affect your ability to drive and use machines or work without safe
foothold.
Tesavel contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially
 sodium-free .</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tesavel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tesavel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist
if you are not sure.
The usual recommended dose is:</p>
<p>one 100 mg film-coated tablet </p>
<p>once a day</p>
<p>by mouth
If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg).
You can take this medicine with or without food and drink.
Your doctor may prescribe this medicine alone or with certain other medicines that lower blood sugar.
Diet and exercise can help your body use its blood sugar better. It is important to stay on the diet and
exercise recommended by your doctor while taking Tesavel.
If you take more Tesavel than you should
If you take more than the prescribed dosage of this medicine, contact your doctor immediately.
If you forget to take Tesavel
If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your
next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose of
this medicine.
If you stop taking Tesavel
Continue to take this medicine as long as your doctor prescribes it so you can continue to help control
your blood sugar. You should not stop taking this medicine without talking to your doctor first. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
STOP taking Tesavel and contact a doctor immediately if you notice any of the following serious side
effects:
* Severe and persistent pain in the abdomen (stomach area) which might reach through to your
back with or without nausea and vomiting, as these could be signs of an inflamed pancreas
(pancreatitis). 
If you have a serious allergic reaction (frequency not known), including rash, hives, blisters on the
skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in
breathing or swallowing, stop taking this medicine and call your doctor right away. Your doctor may
prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.
Some patients have experienced the following side effects after adding sitagliptin to metformin:
Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting
Uncommon (may affect up to 1 in 100 people): stomach ache, diarrhoea, constipation, drowsiness
Some patients have experienced different types of stomach discomfort when starting the combination
of sitagliptin and metformin together (frequency is common).
Some patients have experienced the following side effects while taking sitagliptin in combination with
a sulphonylurea and metformin:
Very common (may affect more than 1 in 10 people): low blood sugar
Common: constipation
Some patients have experienced the following side effects while taking sitagliptin and pioglitazone:
Common: flatulence, swelling of the hands or legs
Some patients have experienced the following side effects while taking sitagliptin in combination with
pioglitazone and metformin:
Common: swelling of the hands or legs
Some patients have experienced the following side effects while taking sitagliptin in combination with
insulin (with or without metformin): 
Common: flu
Uncommon: dry mouth
Some patients have experienced the following side effects while taking sitagliptin alone in clinical
studies, or during post-approval use alone and/or with other diabetes medicines:
Common: low blood sugar, headache, upper respiratory infection, stuffy or runny nose and sore throat,
osteoarthritis, arm or leg pain
Uncommon: dizziness, constipation, itching
Rare: reduced number of platelets
Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle
pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly via the national reporting
system listed in Appendix V. By reporting side effects you can help provide more information on the
safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tesavel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tesavel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after 'EXP'.
The expiry date refers to the last day of that month.
Store below 25  C.
Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tesavel contains
- The active substance is sitagliptin:<em> 
Each Tesavel 25 mg film-coated tablet (tablet) contains sitagliptin phosphate
monohydrate, equivalent to 25 mg sitagliptin.</em> 
Each Tesavel 50 mg film-coated tablet (tablet) contains sitagliptin phosphate
monohydrate, equivalent to 50 mg sitagliptin.<em> 
Each Tesavel 100 mg film-coated tablet (tablet) contains sitagliptin phosphate
monohydrate, equivalent to 100 mg sitagliptin.
- The other ingredients are:</em> 
Tablet core: microcrystalline cellulose (E460), calcium hydrogen phosphate, anhydrous
(E341), croscarmellose sodium (E468), magnesium stearate (E470b), sodium stearyl
fumarate and propyl gallate. * 
Film coating: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171),
red iron oxide (E172), and yellow iron oxide (E172).
What Tesavel looks like and contents of the pack
- Tesavel 25 mg film-coated tablets are round, pink film-coated tablets with  221  on one side.
- Tesavel 50 mg film-coated tablets are round, light beige film-coated tablets with  112  on one
side.
- Tesavel 100 mg film-coated tablets are round, beige film-coated tablets with  277  on one side.
Opaque blisters (PVC/PE/PVDC and aluminium). Packs of 14, 28, 30, 56, 84, 90 or 98 film-coated
tablets and 50 x 1 film-coated tablets in perforated unit dose blisters.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgique/Belgi /Belgien
MSD Belgium
T l/Tel: +32 (0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370 5 278 02 msd_lietuva@merck.com</p>
<p>.: +359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l: +32 (0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft.
Tel.: +36 1 888 53 hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: +45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel.: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel: +372 6144 msdeesti@merck.com 
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no
E 
MSD  . . . . .
 : + 30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Almirall, S.A.
Tel: +34 93 291 30 info.spain@almirall.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: + 33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 66 11 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: + 4021 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila
d.o.o. 
Tel: + 386 1 5204 msd_slovenia@merck.com
 sland
Vistor hf.
S mi: +354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r. o.
Tel.: +421 2 58282dpoc_czechslovak@merck.com
 talia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0) 9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 : 80000 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371 67364 msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human
Health) Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu.</p>         </div>"""      



Instance: composition-da-118afad7684b14db488523a58f186d8f
InstanceOf: CompositionUvEpi
Title: "Composition for tesavel Package Leaflet"
Description:  "Composition for tesavel Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfa38344eb5b5d2eb2ddb54f7e79c6b96)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tesavel"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal De vide, før De begynder at tage Tesavel
3. Sådan skal De tage Tesavel
4. Bivirkninger 
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tesavel is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tesavel is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tesavel indeholder det aktive stof sitagliptin, som tilhører en klasse af lægemidler, som kaldes DPP-4-
hæmmere (dipeptylpeptidase-4-hæmmere). Disse lægemidler sænker blodsukkeret hos voksne
patienter med type 2-diabetes mellitus. 
Dette lægemiddel hjælper med at øge mængden af insulin, der frigives efter et måltid, og nedsætter
mængden af sukker, der dannes af kroppen. 
Deres læge har foreskrevet dette lægemiddel som en hjælp til at sænke Deres blodsukker, som er for
højt på grund af Deres type 2-diabetes. Lægemidlet kan bruges alene eller sammen med visse andre
lægemidler (insulin, metformin, sulfonylurinstof eller glitazoner), som sænker blodsukkeret, og som
De måske allerede tager for Deres diabetes, samtidig med at De følger en diæt- og  motionsplan. 
Hvad er type 2-diabetes?
Type 2-diabetes er en tilstand, hvor Deres krop ikke danner nok insulin, samtidig med at det insulin,
som Deres krop danner, ikke virker så godt, som det burde. Deres krop kan også danne for meget
sukker. Når dette sker, øges sukkerindholdet (glucose) i blodet. Dette kan føre til alvorlige
helbredsproblemer som hjertesygdom, nyresygdom, blindhed og amputation.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tesavel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tesavel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Tesavel
- hvis De er allergisk over for sitagliptin eller et af de øvrige indholdsstoffer i Tesavel (angivet i
punkt 6).
34
Advarsler og forsigtighedsregler
Der er indberettet tilfælde af betændelse i bugspytkirtlen (pankreatitis) hos patienter, der får Tesavel
(se punkt 4). 
Hvis De får blærer på huden, kan det være et tegn på en hudsygdom kaldet bulløs pemfigoid. Lægen
vil måske bede Dem om at stoppe med at tage Tesavel.
Fortæl Deres læge, om De har eller har haft:</p>
<ul>
<li>En sygdom i bugspytkirtlen (f.eks. pankreatitis).</li>
<li>Galdesten, alkoholafhængighed eller et meget højt indhold af triglycerider (en fedtstoftype) i
blodet. Disse sygdomme kan forøge risikoen for at få pankreatitis (se punkt 4).</li>
<li>Type 1-diabetes.</li>
<li>Komplikation til diabetes med forhøjet blodsukker, hurtigt vægttab, kvalme eller opkastning
(diabetisk ketoacidose).</li>
<li>Tidligere eller nuværende nyreproblemer. </li>
<li>Allergisk reaktion over for Tesavel (se punkt 4).
Dette lægemiddel vil ikke forårsage lavt blodsukker, fordi det ikke virker, når Deres blodsukker er
lavt. Når lægemidlet tages sammen med et sulfonylurinstof eller sammen med insulin kan lavt
blodsukker (hypoglykæmi) forekomme. Lægen vil måske nedsætte dosis af sulfonylurinstof eller
insulin.
Børn og unge
Dette lægemiddel må ikke anvendes til børn og unge under 18 år. Det er ikke effektivt hos børn og
unge i alderen 10 til 17 år. Det er ukendt, om dette lægemiddel er sikkert og effektivt, når det
anvendes hos børn under 10 år.
Brug af anden medicin sammen med Tesavel
Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin, for nylig har brugt
anden medicin eller planlægger at bruge anden medicin.
Fortæl det især til lægen, hvis De tager digoxin (et lægemiddel til behandling af uregelmæssig
hjerterytme og andre hjerteproblemer). Det kan være nødvendigt at kontrollere indholdet af digoxin i
Deres blod, hvis De tager Tesavel.
Graviditet og amning
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. De bør ikke tage
dette lægemiddel under graviditet. 
Det er ukendt, om lægemidlet går over i modermælken. De bør ikke tage dette lægemiddel, hvis De
ammer eller planlægger at amme.
Trafik- og arbejdssikkerhed
Lægemidlet påvirker ikke eller kun i ubetydelig grad evnen til at køre bil eller betjene maskiner. Der
har dog været rapporter om svimmelhed og døsighed, som kan påvirke Deres evne til at køre bil eller
betjene maskiner. 
Hvis De tager dette lægemiddel sammen med medicin, der kaldes sulfonylurinstof eller sammen med
insulin, kan det medføre for lavt blodsukker (hypoglykæmi), som kan påvirke Deres evne til at køre
bil og betjene maskiner eller hvis De arbejder uden sikkert fodfæste.
Tesavel indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det
væsentlige natriumfrit.
35</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tesavel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tesavel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller
apotekspersonalet. 
Den almindelige anbefalede dosis er:</p>
<ul>
<li>
<p>En 100 mg filmovertrukken tablet.</p>
</li>
<li>
<p>En gang dagligt.</p>
</li>
<li>
<p>Gennem munden.
Hvis De har nyreproblemer, kan Deres læge ordinere en lavere dosis (såsom 25 mg eller 50 mg).
De kan tage dette lægemiddel med eller uden mad og drikke.
Deres læge kan ordinere dette lægemiddel alene eller sammen med visse andre lægemidler, der sænker
blodsukkeret.
Diæt og motion kan hjælpe Dem, så kroppen bruger sit blodsukker bedre. Det er vigtigt at forblive på
den diæt og motion, som lægen anbefaler, mens De tager Tesavel.
Hvis De har taget for meget Tesavel
Kontakt straks Deres læge, hvis De har taget mere end den foreskrevne dosis af dette lægemiddel.
Hvis De har glemt at tage Tesavel
Hvis De glemmer en dosis, så tag den, så snart De kommer i tanke om det. Hvis De ikke kommer i
tanke om det, før det er tid til næste dosis, skal De springe den glemte dosis over og tage den næste
dosis som normalt. De må ikke tage en dobbeltdosis som erstatning for den glemte dosis af
lægemidlet.
Hvis De holder op med at tage Tesavel
Fortsæt med at tage dette lægemiddel, så længe Deres læge ordinerer det, så De fortsat kan få hjælp til
at kontrollere Deres blodsukker. De bør ikke holde op med at tage dette lægemiddel uden at tale med
lægen først.
Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om.</p>
</li>
</ul>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
STOP med at tage Tesavel og kontakt straks lægen, hvis De får nogen af følgende alvorlige
bivirkninger:</p>
<ul>
<li>Svære og vedvarende smerter i maven, som kan stråle ud i ryggen, med eller uden kvalme og
opkastning, da det kan være tegn på betændelse i bugspytkirtlen (pankreatitis).
Hvis De får en alvorlig allergisk reaktion (hyppighed ikke kendt), herunder udslæt, nældefeber, blærer
på huden/hudafskalning og hævelse af ansigt, læber, tunge og svælg, som kan medføre vejrtræknings-
og synkebesvær, skal De stoppe med at tage dette lægemiddel og kontakte lægen omgående. Lægen
kan ordinere et lægemiddel til behandling af Deres allergiske reaktion og et andet lægemiddel til Deres
diabetes.
Nogle patienter har oplevet følgende bivirkninger, efter at sitagliptin er blevet føjet til metformin:
Almindelige (kan berøre op til 1 ud af 10): lavt blodsukker, kvalme, øget luftafgang fra tarmen,
opkastning.
Ikke almindelige (kan berøre op til 1 ud af 100): Mavesmerter, diarré, forstoppelse, døsighed.
36
Nogle patienter har oplevet forskellige typer mavegener, når de er startet med at kombinere sitagliptin
og metformin (hyppighed: almindelig).
Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin sammen med et
sulfonylurinstof og metformin:
Meget almindelig (kan berøre flere end 1 ud af 10) : Lavt blodsukker.
Almindelig: Forstoppelse.
Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin og pioglitazon:
Almindelige: Øget luftafgang fra tarmen, hævede hænder eller ben. 
Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin sammen med pioglitazon
og metformin:
Almindelige: Hævede hænder eller ben.
Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin sammen med insulin
(med eller uden metformin):
Almindelig: Influenza
Ikke almindelig: Tør mund
Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin alene i kliniske studier
eller ved anvendelse efter markedsføring alene og/eller sammen med anden diabetesmedicin:
Almindelige: Lavt blodsukker, hovedpine, infektion i øvre luftveje, stoppet næse eller snue og ondt i
halsen, betændelse i led og den tilgrænsede knogle, smerter i arme eller ben toppet eller løbende næse
og ondt i halsen, osteoartrit (betændelse i led og knogler), smerter i arme eller ben.
Ikke almindelige: Svimmelhed, forstoppelse, kløe.
Sjælden: Nedsat antal blodplader.
Hyppighed ikke kendt: nyreproblemer (som kan kræve dialyse), opkastning, ledsmerter,
muskelsmerter, rygsmerter, interstitiel lungesygdom, bulløs pemfigoid (en type blærer på huden).
Indberetning af bivirkninger
Hvis De oplever bivirkninger, bør De tale med Deres læge, apotekspersonalet eller sygeplejersken.
Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at
fremskaffe mere information om sikkerheden af dette lægemiddel.</li>
</ul>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tesavel"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tesavel"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og kartonen efter EXP. Udløbsdatoen
er den sidste dag i den nævnte måned.
Opbevares ved temperaturer under 25 °C.
Spørg apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke
smide medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tesavel indeholder:</p>
<ul>
<li>Aktivt stof: sitagliptin: * 
Hver Tesavel 25 mg filmovertrukken tablet (tablet) indeholder sitagliptin
phosphatmonohydrat, der svarer til 25 mg sitagliptin.
37<em> 
Hver Tesavel 50 mg filmovertrukken tablet (tablet) indeholder sitagliptin
phosphatmonohydrat, der svarer til 50 mg sitagliptin.</em> 
Hver Tesavel 100 mg filmovertrukken tablet (tablet) indeholder sitagliptin
phosphatmonohydrat, der svarer til 100 mg sitagliptin.</li>
<li>Øvrige indholdsstoffer: * 
Tabletkerne: mikrokrystallinsk cellulose (E460), calciumhydrogenphosphat, vandfrit
(E341), croscarmellosenatrium (E468), magnesiumstearat (E470b),
natriumstearylfumarat og propylgallat. * 
Filmovertræk: poly(vinylalkohol), macrogol 3350, talcum (E553b), titandioxid (E171),
rød jernoxid (E172) og gul jernoxid (E172).
Udseende og pakningsstørrelser</li>
<li>Tesavel 25 mg filmovertrukne tabletter er runde, lyserøde, filmovertrukne tabletter mærket med
"221" på den ene side.</li>
<li>Tesavel 50 mg filmovertrukne tabletter er runde, lys beige, filmovertrukne tabletter mærket med
"112" på den ene side.</li>
<li>Tesavel 100 mg filmovertrukne tabletter er runde, beige, filmovertrukne tabletter mærket med
"277" på den ene side.
Uigennemsigtig blister (PVC/PE/PVDC og aluminium). Pakninger med 14, 28, 30, 56, 84, 90 eller
98 filmovertrukne tabletter og 50 x 1 filmovertrukne tabletter i perforerede enkeltdosisblistre.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen og fremstiller
Merck Sharp &amp; Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Holland
Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
Belgique/België/Belgien
MSD Belgium
Tél/Tel: +32 (0)27766211
dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370 5 278 02 47
msd_lietuva@merck.com
България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
Tél: +32 (0)27766211
dpoc_belux@merck.com
Česká republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 111
dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft.
Tel.: +36 1 888 53 00
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: +45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
38
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland 
Merck Sharp &amp; Dohme B.V.
Tel.: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com 
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Eλλάδα
MSD Α .Φ.Β.Ε.Ε
Τηλ: +30-210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Almirall, S.A.
Tel: +34 93 291 30 00
info.spain@almirall.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 00
msdpolska@merck.com
France
MSD France
Tél: +33 (0) 1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 66 11 333
croatia_info@merck.com
România
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: + 4021 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila
d.o.o. 
Tel: + 386 1 5204 201
msd_slovenia@merck.com
Ísland
Vistor hf.
Sími: +354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s.r.o.
Tel.: +421 2 58282010
dpoc_czechslovak@merck.com
Ιtalia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0) 9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ: 80000 673 (+357 22866700)
cyprus_info@merck.com 
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
39
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371 67364 224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human
Health) Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}
De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.</li>
</ul>         </div>"""      





                    
Instance: bundlepackageleaflet-en-118afad7684b14db488523a58f186d8f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tesavel Package Leaflet for language en"
Description: "ePI document Bundle for tesavel Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-118afad7684b14db488523a58f186d8f"
* entry[0].resource = composition-en-118afad7684b14db488523a58f186d8f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp118afad7684b14db488523a58f186d8f"
* entry[=].resource = mp118afad7684b14db488523a58f186d8f
                            
                    
Instance: bundlepackageleaflet-da-118afad7684b14db488523a58f186d8f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tesavel Package Leaflet for language da"
Description: "ePI document Bundle for tesavel Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-118afad7684b14db488523a58f186d8f"
* entry[0].resource = composition-da-118afad7684b14db488523a58f186d8f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp118afad7684b14db488523a58f186d8f"
* entry[=].resource = mp118afad7684b14db488523a58f186d8f
                            
                    



Instance: mp118afad7684b14db488523a58f186d8f
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product tesavel"
Description: "tesavel"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Tesavel 25 mg film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "For adult patients with type 2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "tesavel"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 118afad7684b14db488523a58f186d8fListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tesavel"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tesavel"

* subject = Reference(mpfa38344eb5b5d2eb2ddb54f7e79c6b96)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tesavel "tesavel"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-118afad7684b14db488523a58f186d8f) // tesavel en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-118afad7684b14db488523a58f186d8f) // tesavel da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-118afad7684b14db488523a58f186d8f
InstanceOf: List

* insert 118afad7684b14db488523a58f186d8fListRuleset
    